Keith Wayne Ward Net Worth

The estimated Net Worth of Keith Wayne Ward is at least $8.34 Million dollars as of 25 February 2019. Keith Ward owns over 40,367 units of Reata Pharmaceuticals Inc stock worth over $1,485,743 and over the last 8 years Keith sold RETA stock worth over $6,852,651.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Keith Ward RETA stock SEC Form 4 insiders trading

Keith has made over 8 trades of the Reata Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Keith sold 40,367 units of RETA stock worth $3,678,645 on 25 February 2019.

The largest trade Keith's ever made was selling 40,367 units of Reata Pharmaceuticals Inc stock on 25 February 2019 worth over $3,678,645. On average, Keith trades about 7,548 units every 19 days since 2016. As of 25 February 2019 Keith still owns at least 8,620 units of Reata Pharmaceuticals Inc stock.

You can see the complete history of Keith Ward stock trades at the bottom of the page.

What's Keith Ward's mailing address?

Keith's mailing address filed with the SEC is 2801 Gateway Dr #150, Irving, TX 75063, USA.

Insiders trading at Reata Pharmaceuticals Inc

Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy, and Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.

What does Reata Pharmaceuticals Inc do?

reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Complete history of Keith Ward stock trades at Reata Pharmaceuticals Inc

Reata Pharmaceuticals Inc executives and stock owners

Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Manmeet Soni,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President
• J. Warren Huff,
  Chairman of the Board, President, Chief Executive Officer
• Colin Meyer,
  Executive Vice President, Chief Research and Development Officer
• Michael Wortley,
  Executive Vice President, Chief Legal Officer
• Dawn Bir,
  Executive Vice President, Chief Commercial Officer
• Manmeet Singh Soni,
  COO, CFO & Pres
• J. Warren Huff,
  Chairman & CEO
• Dr. Colin J. Meyer M.D.,
  Exec. VP & Chief Innovation Officer
• Michael D. Wortley,
  Exec. VP & Chief Legal Officer
• Dawn Carter Bir,
  Exec. VP & Chief Commercial Officer
• Jack Nielsen,
  Independent Director
• William McClellan,
  Independent Director
• William Rose,
  Independent Director
• R. Kent McGaughy,
  Independent Director
• Vineet Jindal,
  Vice President, Corporate Communications and Strategy
• Martin Edwards,
  Independent Director
• Seemi Khan,
  Chief Medical Officer
• Andrea Loewen,
  Vice President - Global Regulatory Affairs
• Kevin Johnston,
  Chief Technical Officer, Vice President
• Steve Harman,
  VP & Chief HR Officer
• Dakota Gallivan,
  VP & Chief Healthcare Compliance Officer
• Dr. W. Christian Wigley Ph.D.,
  Sr. VP & Chief Scientific Officer
• Bhaskar Anand,
  VP & Chief Accounting Officer
• William Puffin Partners, L....,
  
• Dennis K. Stone,
  Director
• Elaine Castellanos,
  VP, Chief Accounting Officer
• Holdings A/S Novo,
  10% owner
• James Edward Bass,
  Director
• James W Jr Traweek,
  
• Inc Cpmg,
  
• Inc. Abb Vie,
  10% owner
• Keith Wayne Ward,
  See Remarks
• William Rose Evelyn P.Edwar...,
  
• William Puffin Partners, L....,
  
• Antal Rohit Cpmg Inc Desai,
  
• William Montrose Investment...,
  
• William Charles Henry Rose ...,
  
• William Puffin Partners, L....,
  
• William Estate Of Edward W....,
  
• Jason Douglas Wilson,
  Executive VP of Operations
• Pharma Llcstapleton Craig R...,
  
• Christy J. Oliger,
  Director
• Shamim Ruff,
  Director
• Bhaskar Anand,
  SVP, Chief Accounting Officer
• Steven Ryder,
  Director
• Samina Khan,
  SVP, Chief Medical Officer
• Rajiv Patni,
  EVP, Chief R&D Officer